title: High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy.
authors.affiliation: Departments of Surgery, Kouseiren Takaoka Hospital, Toyama, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kotake
authors.affiliation: Department of Physical Activity Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Murakami
authors.affiliation: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kenmotsu
authors.affiliation: Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Naito
authors.affiliation: Faculty of Pharmaceutical Sciences, Yokohama College of Pharmacy, Kanagawa, Japa
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D000178:Acrylamides; D000230:Adenocarcinoma / Q000188:drug therapy; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000814:Aniline Compounds; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015994:Incidence; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D000077594:Nivolumab; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D007211:Indoles; D011743:Pyrimidines
chemical_list: D000178:Acrylamides; D000814:Aniline Compounds; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab; D010879:Piperazines; C000596361:osimertinib; D007211:Indoles; D011743:Pyrimidines